Madison Investment Advisors LLC Buys Shares of 202,029 Pfizer Inc. (NYSE:PFE)

Madison Investment Advisors LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 202,029 shares of the biopharmaceutical company's stock, valued at approximately $5,360,000.

Several other institutional investors have also recently bought and sold shares of PFE. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Raymond James Financial Inc. bought a new position in Pfizer in the 4th quarter worth approximately $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after buying an additional 6,977,587 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after acquiring an additional 4,938,209 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after acquiring an additional 4,726,549 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Finally, Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Price Performance

Shares of PFE traded down $0.58 during trading hours on Tuesday, hitting $25.56. The stock had a trading volume of 47,457,417 shares, compared to its average volume of 36,645,983. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a market capitalization of $144.96 billion, a price-to-earnings ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61. The company's fifty day moving average is $26.15 and its two-hundred day moving average is $27.02. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the business posted $0.10 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.